Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
Sponsor: Ono Pharmaceutical Co. Ltd
Summary
To investigate the tolerability and safety of ONO-7913 and ONO-4538 used in combination with modified FOLFIRINOX (mFFX therapy), the standard of care, as first-line treatment in patients with metastatic pancreatic cancer.
Key Details
Gender
All
Age Range
20 Years - Any
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2021-07-30
Completion Date
2026-12-31
Last Updated
2024-11-14
Healthy Volunteers
No
Conditions
Interventions
ONO-7913
Specified dose on specified days
ONO-4538
Specified dose on specified days
Oxaliplatin
Specified dose on specified days
Levofolinate
Specified dose on specified days
Irinotecan
Specified dose on specified days
Fluorouracil
Specified dose on specified days
Locations (9)
National Cancer Center Hospital East
Kashiwa-shi, Chiba, Japan
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan
Seirei Hamamatsu General Hospital
Hamamatsu, Shizuoka, Japan
Juntendo University Hospital
Bunkyō-Ku, Tokyo, Japan
The University of Tokyo Hospital
Bunkyō-Ku, Tokyo, Japan
The Cancer Institute Hospital ofJFCR
Koto-ku, Tokyo, Japan
Kyorin University Hospital
Mitaka-shi, Tokyo, Japan
Keio University Hospital
Shinjuku-Ku, Tokyo, Japan
National Cancer Center Hospital
Chūōku, Japan